12.11.2023
... wird von Alnylam und Roche gemeinsam entwickelt und vermarktet. ... und Vertrieb bestimmter Produkte, einschließlich Roche, Novartis, Sanofi, Regeneron ...
11.11.2023
... Lanxess 1,91%, Linde 0,05%, Roche GS -0,02%, Stratec Biomedical -0,22 ... -4,53% , Merck KGaA -4,81% , Roche GS -5,08% , Paion -5,2% , Epigenomics ...
11.11.2023
... IBM 0,76%, Intel 0,27%, Roche GS -0,02%, Novartis -0,43%, Cisco ... % , voestalpine -3,73% , Novartis -4,35% , Roche GS -5,08% , Zumtobel -6,75% , Johnson ...
04.11.2023
... Biogen Idec 0,32%, Linde 0,05%, Roche GS -0,21%, Novartis -0,5%, Amgen -1, ... Evotec -0,11% , BB Biotech -2,86% , Roche GS -3,69% , Bayer -4,15% , Biogen ...
04.11.2023
... 88%, Johnson & Johnson 0,83%, Roche GS -0,21%, Novartis -0,5%, Honda ... Johnson -3,16% , Volkswagen -3,22% , Roche GS -3,69% , Alphabet -4,88% , Zumtobel ...
01.11.2023
... .32% Polytec Group PYT 4 4.71% Roche Holding RHO 247.2 -3.44% Wirecard ...
31.10.2023
... ) PENCE - JPMORGAN SENKT ZIEL FÜR ROCHE AUF 245 (260) CHF - 'UNDERWEIGHT ...
28.10.2023
... -0,4%, Baxter International -0,49%, Roche GS -0,5%, BASF -0,59%, Fresenius ... Sanofi -2,12% , BASF -3,73% , Roche GS -4,93% , Paion -5,2% , Biogen ...